BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|July 2, 2003
- Pharmaceutical Technology-07-02-2003
- Volume 27
- Issue 7
Capacity Worries Fade for Biomanufacturing
Author(s)Jim Miller
The DSM investment puts biomanufacturing capacity in the spotlight. Contract biomanufacturers are adding new capacity and sponsors are marketing their excess capacity.
Advertisement
Articles in this issue
over 23 years ago
July 2003over 23 years ago
The Push for Generics Challenges Manufacturersover 23 years ago
Emerging Research Opportunities in Oral Inhalation Technologyover 23 years ago
Preventing Metal ContaminationAdvertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AI Formulation: Regulators Want Data
2
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
5